נולוג'יקס 250 מ"ג

Country: Iżrael

Lingwa: Ebrajk

Sors: Ministry of Health

Ingredjent attiv:

BELATACEPT 25 MG/ML

Disponibbli minn:

BRISTOL-MYERS SQUIBB (ISRAEL) LIMITED

Kodiċi ATC:

L04AA28

Għamla farmaċewtika:

POWDER FOR CONCENTRATE FOR INFUSION

Rotta amministrattiva:

I.V

Manifatturat minn:

BRISTOL-MYERS SQUIBB S.R.L, ITALY

Grupp terapewtiku:

BELATACEPT

Indikazzjonijiet terapewtiċi:

Nulojix, in combination with corticosteroids and mycophenolic acid (MPA), is indicated for prophylaxis of graft rejection in adults receiving a renal transplant. It is recommended to add an interleukin (IL)-2 receptor antagonist for induction therapy to this belatacept-based regimen

Data ta 'l-awtorizzazzjoni:

2012-08-01